cognitive cybersecurity intelligence

News and Analysis


Using ripretinib and surgery to manage recurrent gastrointestinal stromal tumor

Researchers from The University of Texas MD Anderson Cancer Center and Sarah Cannon Research Institute have used ripretinib and surgical removal of a tumour to successfully treat a patient with recurring gastrointestinal cancer, carrying a KIT exon 11 mutation. The patient received 43 months of treatment, longer than current ripretinib clinical trials, which are reported to have improved clinical outcomes.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts